Add this topic to your myFT Digest for news straight to your inbox
Research forecasts global deaths from the disease will almost double in 20 years
It aims to exploit its extraordinary cache of genetic data but changing corporate DNA is hard
WHO member states are struggling to agree the terms of the first global treaty to deal with the threat of another Covid-19
Patients who took Sanofi’s lixisenatide experienced no worsening of motor symptoms
Europe’s regulations have become ‘too burdensome’ and could hinder innovation, argues Michael Lohan
Widespread testing for this treatable if embarrassing condition is being hampered by lack of access to healthcare
Novo Nordisk and Eli Lilly, plus a clutch of rivals, aim to cut side effects while treating obesity-linked diseases
UK pharma group’s chief has a fresh challenge — persuading investors that its best days are not behind it
Shareholder advisory groups say potential £18.7mn payout is excessive
Not only is the cost-benefit ratio unbeatable, but not to undertake this spending is to court disaster
Aardvark Therapeutics’ drug has been shown in trials to suppress cravings in patients with rare genetic form of obesity
Record shortages of common drugs have countries scrambling for alternatives while patients skip treatments
Justices’ scepticism towards disrupting the legal landscape is a potential boon for Republicans ahead of 2024 election
David Neal, sacked last month, says Home Office did not understand sector and left migrants open to exploitation
Transformative changes are still 10 to 15 years away, experts predict
Danish group seeks to branch out from diabetes and weight loss drugs with Cardior acquisition
Madrigal is the first to win approval for a treatment for a liver disease that affects one in 20
Shadow health secretary says that in the longer term, he would like no one to need to go private
Four years after lockdowns began we are still learning about pandemic hangovers
US award is latest problem for consumer group after disastrous baby formula acquisition
Advocate general of bloc’s top court says decision against world’s biggest gene sequencing group should be annulled
Funding needed to drive innovation and make therapies available to all, says co-discoverer Jennifer Doudna
Lenmeldy gene therapy treats MLD, a condition that attacks the central nervous system of young children
There is an opportunity for local pharma groups, which Nomura says could take a fifth of the market by 2033
Ruth McKernan aims to make country a hub for research into the condition and accelerate development of new drugs
International Edition